Skip to main content

Abemaciclib, Ribociclib, or Palbociclib for HR+ Metastatic Breast Cancer?

Breast Cancer, Video, SABCS Highlights
Conference Correspondent 
Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA-approved for HR+ metastatic breast cancer, from ribociclib and palbociclib.

Related Items

Adding Ribociclib to Endocrine Therapy May Reduce Risk for Recurrence in HR-Positive, HER2-Negative, Early Breast Cancer
By Patricia Stewart
July 2023 Vol 16, No 4 – Online Only
ASCO 2023 Highlights, Breast Cancer
FDA Updates Mammography Regulations in MQSA Final Rule
May 2023 Vol 16, No 3
Breast Cancer, Healthcare Policy
Pausing Endocrine Therapy to Become Pregnant Appears Safe for Women with Breast Cancer
By Patricia Stewart
March 2023 Vol 16, No 2
Breast Cancer, SABCS Highlights
First-Line Ribociclib plus Endocrine Therapy Beats Chemotherapy for Advanced Breast Cancer
By William King
January 2023 Vol 16, No 1
SABCS Highlights